NCT03012100: A trial that was reported late by Academic and Community Cancer Research United
This trial has reported, although it was 55 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03012100 |
|---|---|
| Title | Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 31, 2017 |
| Completion date | Feb. 28, 2025 |
| Required reporting date | Feb. 28, 2026, midnight |
| Actual reporting date | April 24, 2026 |
| Date last checked at ClinicalTrials.gov | July 3, 2026 |
| Days late | 55 |